Abstract
Prognostic or predictive somatic genetic biomarkers influence therapeutic decisions in oncology. With the availability of next-generation sequencing (NGS) technologies, large numbers of somatic and germ line mutations can be analysed in parallel both, from formalin-fixed, paraffin-embedded tissue (FFPE) and fresh frozen tissue at high quality. In this study we evaluated the feasibility, turn-around time and diagnostic usefulness of highthroughput NGS analyses in the clinical setting and offered two different diagnostic sequencing panels to 52 selected patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
